All News

FDA%20approved.jpg (keep)

Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

d Jack Cush, MD

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.

Read Article
🌟 ASAS researchers recommend using axSpA as the overarching term for axial spondyloarthritis. They prefer radiographic-axSpA over ankylosing spondylitis. These changes aim to standardize terminology and improve clarity in diagnosis and treatment. https://t.co/0IhvwPOfm2 #ASAS https://t.co/H8ummkNmEj

Links:

ASAS Official_ASAS ( View Tweet)
🌟 ASAS researchers recommend using axSpA as the overarching term for axial spondyloarthritis. They prefer radiographic-axSpA over ankylosing spondylitis. These changes aim to standardize terminology and improve clarity in diagnosis and treatment. https://t.co/0IhvwPOfm2 #ASAS https://t.co/H8ummkNmEj

Links:

ASAS Official_ASAS ( View Tweet)
Cancer presenting as Inflammatory low back pain? 34 Cases presenting as SpA over 10 yrs often w/ higher ESR/CRP/LDH levels. CA included myeloma, leukemia, lymphoma, CA of breast/lung/prostate & bone tumors. https://t.co/YYKYx39tbD https://t.co/m9uCbJBsnU

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Systemic Sclerosis Insights (9.13.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
A low risk of Candida infections with ixekizumab (IXE); integrated analysis of 25; Candida infx rates - PsO:1.9/100 PY (N  6892); PsA 2.0/100 PY (N 1401); axSpA 1.2/100PY (N 932). Most occured only once, were mild/moderate & were oral or genital Candida https://t.co/ZkkPoSzPMW https://t.co/VysnaQ8rpi

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Running with Data (8.30.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.

Read Article
Pooled data from BE MOBILE 1 & 2 RCTs shows Bimekizumab (dual-IL-17A/F inhib) may protect against uveitis in axSpA pts. N=349 pts - 0.6% BKZ vs 4.6% placebo developed uveitis (1.8 vs 15.4/100 PYs); even in pts w/ Hx of uveitis (6.2 vs 70/100 PYs; p=0.004) https://t.co/f8Uk0rEg86 https://t.co/mY1ikcGCNP

Links:

Dr. John Cush RheumNow ( View Tweet)
Early axSpA defined by ASAS -- duration of symptoms ≤2 years; axial symptoms defined as cervical/thoracic/back/buttock pain or morning stiffness; regardless of Xray damage. ASAS community endorsed this proposal (88% in favour). https://t.co/JEviEgyIql https://t.co/jw11UsL6Iv

Links:

Dr. John Cush RheumNow ( View Tweet)
antibiotics,pills,capsules

Antibiotics May Increase Inflammatory Arthritis Risk

d Jack Cush, MD

A Danish registry study has shown that amongst those patients who develop inflammatory arthritis (IA), antibiotics use was more frequent when compared to the background population (BP). 

Read Article
Among spondyloarthritis patients with clinical enthesitis, 68% had no ‘active enthesitis’ on ultrasound. Conversely, of those without signs of clinical enthesitis, 15% showed subclinical enthesitis on ultrasound ↓ https://t.co/aVEvOmcEHK

Links:

ACR_Journals ACR_Journals ( View Tweet)
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to SEC 300 mg, but failed to show improvement by week 52. https://t.co/EJvoBlW9or https://t.co/tYb1fIA3pw

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Higher Cancer Rates (8.16.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.

Read Article
SI.Sacroiliitis.AS_.jpg

ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis

d Jack Cush, MD

Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.

Read Article
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/GV6WjsqZBH https://t.co/9l9qyJpg3I

Links:

Dr. John Cush RheumNow ( View Tweet)
CV,risk,MI,heart,cardiac

Less Mortality with GLP-1 Agonists in Rheumatic Patients

d Jack Cush, MD

A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.

Read Article
Depends on Where You’re Looking (8.9.2024) https://t.co/GDAN37DJSx https://t.co/jVoumC00r5

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3

Links:

Dr. John Cush RheumNow ( View Tweet)
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axSpA. https://t.co/lVCdGnMVaT https://t.co/jFILeHrQXj

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×